Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06KZL
|
|||
| Former ID |
DCL001102
|
|||
| Drug Name |
AG140699
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2 | [1] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Pfizer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Poly [ADP-ribose] polymerase 1 (PARP1) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Base excision repair | |||
| NF-kappa B signaling pathway | ||||
| Panther Pathway | FAS signaling pathway | |||
| Pathway Interaction Database | Integrin-linked kinase signaling | |||
| Caspase Cascade in Apoptosis | ||||
| Notch-mediated HES/HEY network | ||||
| Reactome | Dual Incision in GG-NER | |||
| WikiPathways | FAS pathway and Stress induction of HSP regulation | |||
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | ||||
| Nanoparticle triggered regulated necrosis | ||||
| Corticotropin-releasing hormone | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Critical Care Nephrology, Claudio Ronco,Rinaldo Bellomo,John A. Kellum. Page(444). | |||
| REF 2 | Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421-40. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.